ELISA-Kit geliefert von Boster Bio
Know who made it. See the evidence. Buy through one marketplace.
Das Differential Screening-Selected Gene Aberrative in Neuroblastoma (DAN) ist ein Mitglied der DAN-Familie sezernierter Glykoproteine, die mutmaßliche BMP-Antagonisten sind. Das NBL1-Gen, auch bekannt als DAN, wurde ursprünglich aus einer cDNA-Bibliothek von normalen Rattenfibroblasten mittels eines differentiellen Screening-Verfahrens kloniert. Das humane DAN-Gen ist auf Chromosom 1p36.13-p36 kartiert. Es wurde festgestellt, dass das DAN-Gen eine tumorsuppressive Aktivität besitzt, wenn es in v-src-transformierten Zellen überexprimiert wird.
Fully tested in-house by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Sample compatibility evidence using the same validation key.
| Sample type | Probenkompatibilität | Assay-Bereich | Sensitivität | Spezifität |
|---|---|---|---|---|
| Zellkulturüberstände | ||||
| Zelllysate | ||||
| Serum und Plasma (Heparin | ||||
| EDTA). |
This product is manufactured by Boster Bio and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
